Bevacizumab trials for Colorectal cancer

All Bevacizumab trials · All Colorectal cancer trials

Phase breakdown

Recruiting trials studying Bevacizumab for Colorectal cancer

• 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
  NCT06887218 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
  NCT04689347 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
  NCT06839105 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
  NCT07079631 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
  NCT06493760 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer
  NCT07474727 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 19 locations
• A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
  NCT04929223 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 84 locations
• A Study of ASP1002 in Adults for Treatment of Solid Tumors
  NCT05719558 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
  NCT06750094 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 251 locations
• A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
  NCT06730750 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
  NCT07277270 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
  NCT06663319 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
  NCT06792695 · Phase: Phase 2 · Ages: 18 Years to 130 Years · Sex: All (male and female) · 76 locations
• A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
  NCT07549412 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 34 locations
• A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
  NCT05253651 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 366 locations
• A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
  NCT06497985 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
  NCT07525206 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 35 locations
• A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
  NCT06820463 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 65 locations
• A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
  NCT07221357 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 283 locations
• A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
  NCT06948448 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 39 locations
• A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
  NCT06004245 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 43 locations
• A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
  NCT07318805 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• AB122 Platform Study
  NCT04999761 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
  NCT06951503 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer
  NCT06825624 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients
  NCT05797467 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer
  NCT05585814 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
  NCT06540326 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
  NCT06696768 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• Combination Therapy for BRAF-V600E Metastatic CRCm
  NCT06411600 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer
  NCT07389265 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 41 locations
• Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
  NCT06282445 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Evaluating Novel Therapies in ctDNA Positive GI Cancers
  NCT05482516 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• FOG-001 in Locally Advanced or Metastatic Solid Tumors
  NCT05919264 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 33 locations
• FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
  NCT07446322 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
  NCT05727163 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.
  NCT06733038 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 24 locations
• JS212 Combination Therapies in Metastatic Colorectal Cancer
  NCT07503756 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer
  NCT06184698 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
  NCT06280495 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
  NCT06625775 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 88 locations
• Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
  NCT06764680 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer
  NCT07500298 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
  NCT03715933 · Phase: Phase 1 · Ages: 12 Years to 85 Years · Sex: All (male and female) · 36 locations
• Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer
  NCT06341296 · Phase: Phase 2 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 1 location
• Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA
  NCT06307249 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
  NCT05462613 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC
  NCT07549399 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer
  NCT07150247 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
  NCT06047379 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
  NCT06245356 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
  NCT05489211 · Phase: Phase 2 · Ages: 18 Years to 130 Years · Sex: All (male and female) · 96 locations
• Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
  NCT07527858 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
  NCT07775287 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
  NCT06445062 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 64 locations
• Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
  NCT05005403 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 48 locations
• Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
  NCT07222800 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 308 locations
• Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
  NCT02885753 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 49 locations
• Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
  NCT05863195 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 62 locations
• The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer
  NCT05628038 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer
  NCT07204574 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
  NCT06867822 · Phase: Phase 1 · Ages: 19 Years and older · Sex: All (male and female) · 1 location
• Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
  NCT05007132 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.
  NCT07407465 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations

Common questions

How many trials study Bevacizumab for Colorectal cancer?

64 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.